Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | BCL9 | O00512 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4213424 | 0.92 | L3MBTL1 (0.42) | L3MBTL1PKMPLA2G2ABRD4ALDH1A1 | |
| SCHEMBL5046042 | 0.92 | BRD4 (0.43) | L3MBTL1PKMPLA2G2ABRD4SYK | |
| SCHEMBL4218108 | 0.89 | HTT (0.44) | L3MBTL1PKMBRD4ALDH1A1HPGD | |
| SCHEMBL4221109 | 0.87 | ALDH1A1 (0.41) | L3MBTL1PKMBRD4ALDH1A1KDM4E | |
| SCHEMBL4046139 | 0.85 | L3MBTL1 (0.37) | L3MBTL1PKMPLA2G2ABRD4TP53 | |
| SCHEMBL4044752 | 0.85 | L3MBTL1 (0.37) | L3MBTL1PKMPLA2G2ABRD4TP53 | |
| SCHEMBL14011424 | 0.83 | L3MBTL1 (0.36) | L3MBTL1PKMPLA2G2ABRD4 | |
| SCHEMBL4207932 | 0.83 | ADRB2 (0.39) | L3MBTL1ALDH1A1HPGDBCL9CTNNB1 | |
| SCHEMBL4221582 | 0.82 | BCL9 (0.36) | L3MBTL1BRD4SYKBCL9CTNNB1 | |
| SCHEMBL4220227 | 0.80 | BRD4 (0.44) | L3MBTL1PLA2G2ABRD4SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678157-A4 | HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | REDDY US THERAPEUTICS INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7456288-B2 | Heterocyclic compounds and methods of making and using thereof | REDDY US THERAPEUTICS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1678157-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | Reddy US Therapeutics, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050119269-A1 | Heterocyclic compounds and methods of making and using thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-02 | — | — | US | disclosed |
| WO-2005042712-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | REDDY US THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005040163-A1 | HETEROCYCLIC COMPOUNDS THAT BLOCK THE EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGE) | DR. REDDY'S LABORATORIES LTD (IN) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119269-A1 | Heterocyclic compounds and methods of making and using thereof | PYGM, MYLK, HMOX1 | L3MBTL1 4807/4885PKM 446/4885PLA2G2A 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.